{"id":1342,"date":"2023-09-28T18:15:58","date_gmt":"2023-09-28T18:15:58","guid":{"rendered":"https:\/\/naveris.com\/newnaveris\/newnaveris\/?p=1342"},"modified":"2024-12-28T04:57:15","modified_gmt":"2024-12-28T04:57:15","slug":"naveris-announces-new-data-featuring-navdx-in-oral-highlight-and-poster-presentations-at-upcoming-astro-and-aao-hnsf-2023-meetings","status":"publish","type":"post","link":"https:\/\/naveris.com\/newnaveris\/index.php\/naveris-announces-new-data-featuring-navdx-in-oral-highlight-and-poster-presentations-at-upcoming-astro-and-aao-hnsf-2023-meetings\/","title":{"rendered":"Naveris Announces New Data Featuring NavDx\u00ae in Oral Highlight and Poster Presentations at Upcoming ASTRO and AAO-HNSF 2023 Meetings"},"content":{"rendered":"

Waltham, MA., September 28, 2023 –(BUSINESS WIRE<\/a>)–\u00a0Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, today announced that the company will be attending The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNSF) 2023 Annual Meeting in Nashville, Tenn., from September 30-October 4 and The American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting in San Diego, Calif., from October 1-4.<\/span><\/p>\n

\n

 <\/p>\n

Naveris will be exhibiting at both meetings, providing the latest information on NavDx\u00ae, Naveris\u2019 proprietary flagship blood test for tumor tissue modified viral (TTMV\u00ae)-HPV DNA. NavDx is the first and only clinically validated circulating tumor HPV DNA blood test that provides a non-invasive and precise method for detecting molecular residual disease (MRD) before there is clinical or radiographical evidence of cancer recurrence.<\/p>\n

 <\/p>\n

The company will also highlight its TTMV-DNA platform in abstracts selected for oral presentation at both meetings.<\/p>\n

 <\/p>\n

\u201cThere is growing enthusiasm for the use of NavDx in daily practice across the continuum of HPV-driven OPSCC care, especially in the surveillance setting,\u201d said Barry M. Berger, MD, Chief Medical Officer of Naveris. \u201cWe look forward to this new data at the upcoming AAO-HNSF and ASTRO conferences, adding to the accumulation of compelling evidence that is driving clinical adoption of NavDx.\u201d<\/p>\n

 <\/p>\n

Following are details of the abstract that has been accepted for an oral presentation at\u00a0AAO-HNSF 2023<\/a>:<\/p>\n